The interim results of the chronic subQ MGB dosing Phase 2 study for the ... and increasing AI adoption, here’s what we think of Palantir stock. We sell different types of products and services ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and ...

announced today the discontinuation of its Phase 2 clinical study, FIRCE-1, for the treatment of large B-cell lymphoma (LBCL). According to InvestingPro analysis, the company's stock appears ...

In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the other AI ...

We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

A warning of a U.S. stock market bubble, advises diversification into value stocks, commodities, and international equities ...

Artificial intelligence (AI) appears as if it could be one of the game-changing technologies of this generation. Many of the ...

Goldman has previously explained that Phase 3 companies are those with the potential to monetize AI through generating incremental revenues, mostly in software and IT services. Phase 2 represents the ...

DeepSeek, a Chinese artificial intelligence (AI) company that develops large language models (LLMs), turned the world of AI on its head recently when it claimed that it spent just $5.6 million (note ...

Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' vepdegestrant. If the experimental estrogen degrader delays tumor growth longer ...

According to Bank of America, several companies are prime candidates for a stock split in the near future, which could lead to shares doubling the average market return, if historical trends are any ...